|
US2008153894A1
|
|
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
|
AU2007202607A1
|
|
Substituted Pyridinones as Modulators of p38 MAP Kinase
|
|
US2007167621A1
|
|
Substituted pyrimidinones
|
|
OA13332A
|
|
Pyrimidin-4-one derivatives and their use as P38 kinase modulators.
|
|
WO2006079918A1
|
|
Injection device for administering a medication liquid
|
|
EP1794177A2
|
|
Process for preparing 7 -alkoxycarbonyl substituted steroids
|
|
MX2007000749A
|
|
Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist.
|
|
WO2005123701A1
|
|
Method for the preparation of diarylisoxazole sulfonamide compounds and intermediates
|
|
BRPI0508254A
|
|
methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
|
|
US2005261261A1
|
|
Eplerenone drug substance having high phase purity
|
|
BRPI0507436A
|
|
chemically modified human growth hormone receptor antagonist conjugates
|
|
BRPI0507427A
|
|
n-terminally monopeguiled human growth hormone conjugates, processes for their preparation and their methods of use
|
|
AU2004242560A1
|
|
Eplerenone crystalline form
|
|
EP1697346A1
|
|
Crystalline form of 2-{ 4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl} -2-oxoethanol
|
|
BRPI0417197A
|
|
parecoxib metal salts as cox-2 inhibitor prodrugs valdecoxib for treatment of inflammation, pain and / or fever
|
|
BRPI0418115A
|
|
stable liquid growth hormone formulation
|
|
WO2005061485A1
|
|
Process for making substituted pyrazoles
|
|
IL165406D0
|
|
Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX2) inhibitor(s)
|
|
WO2005049014A1
|
|
Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
|
|
WO2005044149A1
|
|
Modified hyaluronic acid polymers
|
